 Anna Bruckner
Concepts (426)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epidermolysis Bullosa | 28 | 2023 | 41 | 7.940 |
Why?
| | Hemangioma | 9 | 2016 | 41 | 2.930 |
Why?
| | Dermatology | 6 | 2023 | 88 | 2.620 |
Why?
| | Epidermolysis Bullosa Dystrophica | 12 | 2023 | 21 | 2.050 |
Why?
| | Skin Neoplasms | 11 | 2022 | 762 | 1.830 |
Why?
| | Acne Vulgaris | 2 | 2022 | 20 | 1.310 |
Why?
| | Epidermolysis Bullosa Simplex | 3 | 2023 | 10 | 1.170 |
Why?
| | Skin | 8 | 2020 | 657 | 1.140 |
Why?
| | Lymphatic Abnormalities | 2 | 2014 | 18 | 0.900 |
Why?
| | Ichthyosis, Lamellar | 3 | 2022 | 10 | 0.850 |
Why?
| | Gentamicins | 1 | 2022 | 42 | 0.840 |
Why?
| | Chilblains | 1 | 2020 | 2 | 0.770 |
Why?
| | Alopecia | 2 | 2012 | 34 | 0.760 |
Why?
| | Humans | 93 | 2023 | 118972 | 0.760 |
Why?
| | Betacoronavirus | 2 | 2020 | 254 | 0.750 |
Why?
| | Dermatitis, Allergic Contact | 4 | 2002 | 60 | 0.740 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2020 | 33 | 0.720 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2020 | 34 | 0.720 |
Why?
| | Child | 40 | 2023 | 19129 | 0.710 |
Why?
| | Severity of Illness Index | 7 | 2022 | 2674 | 0.700 |
Why?
| | Isotretinoin | 2 | 2022 | 22 | 0.690 |
Why?
| | Exanthema | 1 | 2020 | 77 | 0.690 |
Why?
| | Diagnosis, Differential | 13 | 2015 | 1384 | 0.680 |
Why?
| | Pandemics | 4 | 2023 | 1355 | 0.660 |
Why?
| | Skin Diseases | 3 | 2011 | 125 | 0.660 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 348 | 0.650 |
Why?
| | Infant | 23 | 2022 | 8293 | 0.650 |
Why?
| | Coronavirus Infections | 2 | 2020 | 339 | 0.650 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 143 | 0.650 |
Why?
| | Mandelic Acids | 1 | 2018 | 1 | 0.650 |
Why?
| | Parasympatholytics | 1 | 2018 | 14 | 0.640 |
Why?
| | Hyperhidrosis | 1 | 2018 | 5 | 0.640 |
Why?
| | GTP-Binding Protein alpha Subunits | 2 | 2016 | 13 | 0.620 |
Why?
| | Education, Distance | 1 | 2017 | 36 | 0.610 |
Why?
| | Telemedicine | 2 | 2023 | 664 | 0.590 |
Why?
| | Vascular Neoplasms | 2 | 2016 | 16 | 0.580 |
Why?
| | Dermatitis, Atopic | 2 | 2017 | 332 | 0.570 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2016 | 56 | 0.560 |
Why?
| | Histiocytosis | 1 | 2015 | 8 | 0.550 |
Why?
| | Epidermolysis Bullosa, Junctional | 3 | 2021 | 3 | 0.550 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 24 | 0.540 |
Why?
| | Alopecia Areata | 2 | 2022 | 11 | 0.520 |
Why?
| | Nevus, Pigmented | 1 | 2015 | 33 | 0.510 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2015 | 35 | 0.510 |
Why?
| | Anemia | 5 | 2023 | 146 | 0.510 |
Why?
| | Rare Diseases | 1 | 2015 | 113 | 0.510 |
Why?
| | Thrombocytopenia | 2 | 2016 | 185 | 0.500 |
Why?
| | Endothelium, Lymphatic | 1 | 2014 | 12 | 0.490 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2014 | 22 | 0.490 |
Why?
| | Sweat Gland Neoplasms | 2 | 2011 | 6 | 0.490 |
Why?
| | Hydrops Fetalis | 1 | 2014 | 14 | 0.490 |
Why?
| | Drug Eruptions | 1 | 2013 | 26 | 0.480 |
Why?
| | Propranolol | 2 | 2011 | 54 | 0.460 |
Why?
| | Dermatologic Agents | 1 | 2013 | 57 | 0.460 |
Why?
| | Male | 40 | 2022 | 57801 | 0.450 |
Why?
| | Child, Preschool | 17 | 2020 | 9491 | 0.450 |
Why?
| | Female | 38 | 2022 | 61564 | 0.450 |
Why?
| | Hemangioendothelioma | 1 | 2012 | 13 | 0.440 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2012 | 4 | 0.440 |
Why?
| | Infant, Newborn | 13 | 2016 | 5255 | 0.440 |
Why?
| | Adolescent | 20 | 2022 | 18480 | 0.440 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2013 | 140 | 0.440 |
Why?
| | Langer-Giedion Syndrome | 1 | 2012 | 2 | 0.430 |
Why?
| | Hair Diseases | 1 | 2012 | 6 | 0.430 |
Why?
| | Bone Demineralization, Pathologic | 1 | 2011 | 2 | 0.420 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2012 | 36 | 0.420 |
Why?
| | Sarcoma, Kaposi | 1 | 2012 | 73 | 0.410 |
Why?
| | Ichthyosis | 2 | 2022 | 12 | 0.410 |
Why?
| | Calcification, Physiologic | 1 | 2011 | 34 | 0.410 |
Why?
| | Sulfones | 1 | 2012 | 98 | 0.400 |
Why?
| | Bone Diseases, Metabolic | 2 | 2011 | 60 | 0.400 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 412 | 0.390 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2014 | 454 | 0.390 |
Why?
| | 2-Propanol | 1 | 2011 | 21 | 0.390 |
Why?
| | Hyperpigmentation | 1 | 2011 | 11 | 0.390 |
Why?
| | Facial Dermatoses | 2 | 2010 | 14 | 0.390 |
Why?
| | Facial Neoplasms | 1 | 2011 | 18 | 0.390 |
Why?
| | Bone Density | 2 | 2011 | 449 | 0.390 |
Why?
| | Dermis | 2 | 2011 | 29 | 0.390 |
Why?
| | Gene Deletion | 1 | 2012 | 361 | 0.380 |
Why?
| | Clinical Competence | 1 | 2017 | 951 | 0.380 |
Why?
| | Ferrochelatase | 1 | 2010 | 1 | 0.380 |
Why?
| | Porphyria, Erythropoietic | 1 | 2010 | 2 | 0.380 |
Why?
| | Solvents | 1 | 2011 | 118 | 0.370 |
Why?
| | Tumor Burden | 1 | 2011 | 274 | 0.370 |
Why?
| | Desmoplakins | 1 | 2010 | 19 | 0.370 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2010 | 17 | 0.370 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2275 | 0.360 |
Why?
| | Xanthomatosis | 1 | 2009 | 11 | 0.360 |
Why?
| | Mediastinal Neoplasms | 1 | 2010 | 35 | 0.360 |
Why?
| | Laryngeal Neoplasms | 1 | 2010 | 39 | 0.350 |
Why?
| | Granuloma | 1 | 2010 | 87 | 0.350 |
Why?
| | Piperazines | 1 | 2012 | 316 | 0.350 |
Why?
| | Immunohistochemistry | 5 | 2019 | 1691 | 0.350 |
Why?
| | Consensus | 4 | 2023 | 534 | 0.350 |
Why?
| | Carcinoma | 1 | 2011 | 204 | 0.340 |
Why?
| | Parakeratosis | 1 | 2008 | 1 | 0.330 |
Why?
| | Young Adult | 11 | 2020 | 10793 | 0.330 |
Why?
| | Pruritus | 3 | 2014 | 60 | 0.330 |
Why?
| | Internship and Residency | 1 | 2017 | 1001 | 0.310 |
Why?
| | Canada | 3 | 2020 | 340 | 0.310 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2010 | 301 | 0.310 |
Why?
| | Self-Help Groups | 1 | 2007 | 31 | 0.300 |
Why?
| | Dermatitis, Exfoliative | 1 | 2006 | 4 | 0.300 |
Why?
| | Hand Dermatoses | 1 | 2006 | 8 | 0.300 |
Why?
| | Immunoglobulin A | 3 | 2018 | 174 | 0.290 |
Why?
| | Ethics, Medical | 1 | 2007 | 73 | 0.290 |
Why?
| | Prospective Studies | 4 | 2022 | 6471 | 0.280 |
Why?
| | Mutation | 5 | 2018 | 3457 | 0.270 |
Why?
| | Pemphigus | 1 | 2005 | 8 | 0.270 |
Why?
| | Hamartoma | 1 | 2005 | 20 | 0.260 |
Why?
| | Ointments | 2 | 2023 | 25 | 0.260 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1200 | 0.260 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2022 | 610 | 0.260 |
Why?
| | Biopsy, Needle | 3 | 2019 | 190 | 0.250 |
Why?
| | Observer Variation | 4 | 2022 | 309 | 0.250 |
Why?
| | Incontinentia Pigmenti | 1 | 2004 | 3 | 0.250 |
Why?
| | Wound Healing | 2 | 2022 | 270 | 0.240 |
Why?
| | Transcription Factors | 1 | 2012 | 1570 | 0.240 |
Why?
| | Pediatrics | 1 | 2012 | 985 | 0.240 |
Why?
| | Collagen Type VII | 2 | 2021 | 13 | 0.240 |
Why?
| | Aspirin | 1 | 2006 | 334 | 0.240 |
Why?
| | North America | 3 | 2021 | 266 | 0.240 |
Why?
| | Biopsy | 3 | 2015 | 1079 | 0.240 |
Why?
| | Immunoglobulin G | 3 | 2018 | 788 | 0.240 |
Why?
| | Anthraquinones | 1 | 2023 | 8 | 0.230 |
Why?
| | Water | 1 | 2006 | 425 | 0.230 |
Why?
| | Administration, Topical | 3 | 2020 | 141 | 0.230 |
Why?
| | Privacy | 1 | 2023 | 31 | 0.230 |
Why?
| | Decision Support Techniques | 1 | 2007 | 364 | 0.230 |
Why?
| | Excipients | 1 | 2023 | 50 | 0.230 |
Why?
| | Triterpenes | 1 | 2023 | 17 | 0.220 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2006 | 402 | 0.220 |
Why?
| | Confidentiality | 1 | 2023 | 67 | 0.220 |
Why?
| | Retrospective Studies | 12 | 2023 | 12978 | 0.220 |
Why?
| | Skin Care | 2 | 2020 | 18 | 0.220 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2022 | 17 | 0.210 |
Why?
| | Double-Blind Method | 2 | 2023 | 1687 | 0.210 |
Why?
| | Cohort Studies | 4 | 2022 | 5116 | 0.210 |
Why?
| | Anesthetics | 1 | 2022 | 58 | 0.210 |
Why?
| | Jews | 1 | 2021 | 19 | 0.200 |
Why?
| | Administration, Intravenous | 1 | 2022 | 136 | 0.200 |
Why?
| | Rhabdomyosarcoma | 1 | 2022 | 57 | 0.200 |
Why?
| | Fatal Outcome | 2 | 2014 | 287 | 0.200 |
Why?
| | Palliative Care | 1 | 2007 | 629 | 0.190 |
Why?
| | Pseudomonas aeruginosa | 1 | 2023 | 305 | 0.190 |
Why?
| | Adrenal Cortex Hormones | 2 | 2014 | 521 | 0.190 |
Why?
| | Follow-Up Studies | 4 | 2019 | 4596 | 0.190 |
Why?
| | Toes | 1 | 2020 | 26 | 0.190 |
Why?
| | Treatment Outcome | 7 | 2018 | 9342 | 0.190 |
Why?
| | Absorptiometry, Photon | 2 | 2011 | 229 | 0.190 |
Why?
| | NF-kappa B | 1 | 2004 | 670 | 0.180 |
Why?
| | Mycoplasma pneumoniae | 1 | 2020 | 33 | 0.180 |
Why?
| | Iron | 3 | 2023 | 248 | 0.180 |
Why?
| | Detergents | 1 | 2020 | 44 | 0.180 |
Why?
| | Mouth Diseases | 2 | 2013 | 38 | 0.180 |
Why?
| | Mouth Mucosa | 2 | 2013 | 82 | 0.180 |
Why?
| | Prenatal Diagnosis | 2 | 2014 | 168 | 0.180 |
Why?
| | Chronic Pain | 1 | 2022 | 211 | 0.170 |
Why?
| | APOBEC Deaminases | 1 | 2018 | 4 | 0.170 |
Why?
| | Cytosine Deaminase | 1 | 2018 | 14 | 0.170 |
Why?
| | Linear IgA Bullous Dermatosis | 1 | 2018 | 1 | 0.170 |
Why?
| | Administration, Oral | 2 | 2012 | 756 | 0.160 |
Why?
| | Adult | 13 | 2023 | 31512 | 0.160 |
Why?
| | Dilatation | 1 | 2018 | 56 | 0.160 |
Why?
| | Esophageal Stenosis | 1 | 2018 | 47 | 0.160 |
Why?
| | Fluoroscopy | 1 | 2018 | 146 | 0.160 |
Why?
| | Age Distribution | 1 | 2019 | 362 | 0.160 |
Why?
| | Quality of Life | 2 | 2020 | 2366 | 0.160 |
Why?
| | Sex Distribution | 1 | 2019 | 351 | 0.160 |
Why?
| | Patient Satisfaction | 1 | 2022 | 610 | 0.160 |
Why?
| | Cost of Illness | 1 | 2020 | 258 | 0.160 |
Why?
| | Esophagoscopy | 1 | 2018 | 190 | 0.150 |
Why?
| | Databases, Factual | 2 | 2020 | 1231 | 0.150 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2016 | 14 | 0.140 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2016 | 30 | 0.140 |
Why?
| | Staphylococcal Infections | 1 | 2020 | 346 | 0.140 |
Why?
| | Incidence | 2 | 2022 | 2424 | 0.140 |
Why?
| | Risk Assessment | 3 | 2019 | 3057 | 0.140 |
Why?
| | Patient Care Team | 1 | 2020 | 521 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2022 | 532 | 0.130 |
Why?
| | Clobetasol | 1 | 2015 | 4 | 0.130 |
Why?
| | Survival Analysis | 1 | 2019 | 1267 | 0.130 |
Why?
| | Pachyonychia Congenita | 1 | 2015 | 4 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2022 | 4708 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2016 | 298 | 0.130 |
Why?
| | United States | 4 | 2021 | 12555 | 0.130 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 292 | 0.130 |
Why?
| | Middle Aged | 7 | 2020 | 27617 | 0.120 |
Why?
| | Keratins | 1 | 2015 | 174 | 0.120 |
Why?
| | Genes, Recessive | 2 | 2021 | 73 | 0.120 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 156 | 0.120 |
Why?
| | Antigens, CD34 | 1 | 2014 | 98 | 0.120 |
Why?
| | Disease Progression | 2 | 2019 | 2490 | 0.120 |
Why?
| | Prednisolone | 2 | 2013 | 76 | 0.120 |
Why?
| | Caregivers | 1 | 2020 | 709 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1795 | 0.110 |
Why?
| | Transcriptome | 2 | 2018 | 756 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 3 | 2014 | 465 | 0.110 |
Why?
| | Pemphigoid, Bullous | 1 | 2013 | 7 | 0.110 |
Why?
| | Pilot Projects | 1 | 2018 | 1419 | 0.110 |
Why?
| | Remission, Spontaneous | 1 | 2012 | 37 | 0.110 |
Why?
| | Skin Diseases, Papulosquamous | 1 | 2012 | 1 | 0.110 |
Why?
| | Fluorescent Antibody Technique | 2 | 2021 | 410 | 0.110 |
Why?
| | Erythema | 3 | 2022 | 24 | 0.110 |
Why?
| | Prednisone | 2 | 2005 | 235 | 0.110 |
Why?
| | Oropharynx | 1 | 2012 | 41 | 0.110 |
Why?
| | Sildenafil Citrate | 1 | 2012 | 57 | 0.100 |
Why?
| | Panniculitis | 1 | 2011 | 2 | 0.100 |
Why?
| | Actins | 1 | 2014 | 404 | 0.100 |
Why?
| | Nose | 1 | 2012 | 58 | 0.100 |
Why?
| | Carcinoma, Verrucous | 1 | 2011 | 1 | 0.100 |
Why?
| | Fractures, Compression | 1 | 2011 | 13 | 0.100 |
Why?
| | Blood Sedimentation | 1 | 2011 | 34 | 0.100 |
Why?
| | Age Determination by Skeleton | 1 | 2011 | 18 | 0.100 |
Why?
| | Fingers | 1 | 2012 | 83 | 0.100 |
Why?
| | Dwarfism | 1 | 2011 | 17 | 0.100 |
Why?
| | Calcifediol | 1 | 2011 | 29 | 0.100 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1510 | 0.100 |
Why?
| | Subcutaneous Fat | 1 | 2011 | 82 | 0.100 |
Why?
| | Vincristine | 1 | 2011 | 99 | 0.100 |
Why?
| | Purines | 1 | 2012 | 161 | 0.100 |
Why?
| | Mobility Limitation | 1 | 2011 | 62 | 0.100 |
Why?
| | Darier Disease | 1 | 2010 | 2 | 0.100 |
Why?
| | Body Size | 1 | 2011 | 94 | 0.100 |
Why?
| | Hypothermia, Induced | 1 | 2011 | 68 | 0.100 |
Why?
| | Body Height | 1 | 2011 | 187 | 0.100 |
Why?
| | Glucocorticoids | 1 | 2015 | 545 | 0.090 |
Why?
| | Autoantibodies | 1 | 2018 | 1335 | 0.090 |
Why?
| | RNA, Messenger | 2 | 2015 | 2657 | 0.090 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2010 | 34 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2011 | 77 | 0.090 |
Why?
| | Serum Albumin | 1 | 2011 | 146 | 0.090 |
Why?
| | Patch Tests | 2 | 2001 | 50 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2011 | 965 | 0.090 |
Why?
| | Porphyrins | 1 | 2010 | 17 | 0.090 |
Why?
| | Steroids | 1 | 2011 | 153 | 0.090 |
Why?
| | Sequence Analysis, DNA | 2 | 2010 | 755 | 0.090 |
Why?
| | Consanguinity | 1 | 2010 | 49 | 0.090 |
Why?
| | Erythromycin | 1 | 2010 | 25 | 0.090 |
Why?
| | Clarithromycin | 1 | 2010 | 28 | 0.090 |
Why?
| | Foam Cells | 1 | 2009 | 15 | 0.090 |
Why?
| | Infant, Newborn, Diseases | 1 | 2011 | 106 | 0.090 |
Why?
| | Porokeratosis | 1 | 2009 | 1 | 0.090 |
Why?
| | Nevus, Intradermal | 1 | 2009 | 3 | 0.090 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2015 | 540 | 0.090 |
Why?
| | Keratosis | 1 | 2009 | 13 | 0.090 |
Why?
| | Sequence Deletion | 1 | 2010 | 171 | 0.090 |
Why?
| | Staining and Labeling | 1 | 2010 | 146 | 0.090 |
Why?
| | Basement Membrane | 2 | 2007 | 32 | 0.090 |
Why?
| | Epidermodysplasia Verruciformis | 1 | 2009 | 1 | 0.090 |
Why?
| | Respiratory Sounds | 1 | 2010 | 119 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1185 | 0.090 |
Why?
| | Lumbar Vertebrae | 1 | 2011 | 215 | 0.090 |
Why?
| | C-Reactive Protein | 1 | 2011 | 360 | 0.090 |
Why?
| | Radiography | 1 | 2012 | 861 | 0.090 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2010 | 143 | 0.080 |
Why?
| | Hemoglobins | 1 | 2011 | 326 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2011 | 287 | 0.080 |
Why?
| | Dapsone | 2 | 2005 | 5 | 0.080 |
Why?
| | Diaper Rash | 1 | 2008 | 4 | 0.080 |
Why?
| | Blister | 3 | 2013 | 39 | 0.080 |
Why?
| | Immune System Diseases | 1 | 2008 | 35 | 0.080 |
Why?
| | Hair | 1 | 2008 | 68 | 0.080 |
Why?
| | Psychophysiologic Disorders | 1 | 2007 | 11 | 0.080 |
Why?
| | Weight Gain | 1 | 2011 | 493 | 0.080 |
Why?
| | Phenotype | 2 | 2021 | 3003 | 0.080 |
Why?
| | Airway Obstruction | 1 | 2010 | 168 | 0.080 |
Why?
| | Biomedical Research | 1 | 2014 | 612 | 0.080 |
Why?
| | Anti-Anxiety Agents | 1 | 2007 | 38 | 0.080 |
Why?
| | Euthanasia, Passive | 1 | 2007 | 2 | 0.080 |
Why?
| | Ethics Committees | 1 | 2007 | 3 | 0.080 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 907 | 0.080 |
Why?
| | Models, Theoretical | 1 | 2011 | 556 | 0.070 |
Why?
| | Hematinics | 1 | 2006 | 17 | 0.070 |
Why?
| | Androgens | 1 | 2008 | 167 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2011 | 527 | 0.070 |
Why?
| | Patient Advocacy | 1 | 2007 | 66 | 0.070 |
Why?
| | Ferric Compounds | 1 | 2006 | 39 | 0.070 |
Why?
| | Interdisciplinary Communication | 2 | 2020 | 191 | 0.070 |
Why?
| | Aged | 3 | 2020 | 19657 | 0.070 |
Why?
| | Erythropoietin | 1 | 2006 | 82 | 0.070 |
Why?
| | Antidepressive Agents | 1 | 2007 | 189 | 0.070 |
Why?
| | California | 1 | 2007 | 382 | 0.070 |
Why?
| | Desmoglein 3 | 1 | 2005 | 17 | 0.070 |
Why?
| | Genetic Therapy | 1 | 2007 | 267 | 0.070 |
Why?
| | Professional-Family Relations | 1 | 2007 | 133 | 0.070 |
Why?
| | Antipsychotic Agents | 1 | 2007 | 193 | 0.070 |
Why?
| | Physicians | 1 | 2014 | 794 | 0.070 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2005 | 17 | 0.070 |
Why?
| | Colonic Diseases | 1 | 2005 | 26 | 0.070 |
Why?
| | Cellulitis | 1 | 2005 | 47 | 0.070 |
Why?
| | Social Environment | 1 | 2007 | 294 | 0.070 |
Why?
| | Immunosuppressive Agents | 2 | 2015 | 681 | 0.070 |
Why?
| | Dermatitis Herpetiformis | 1 | 2004 | 1 | 0.060 |
Why?
| | Calcium | 1 | 2011 | 1169 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2022 | 2874 | 0.060 |
Why?
| | Epidermis | 1 | 2005 | 152 | 0.060 |
Why?
| | Urticaria | 1 | 2004 | 51 | 0.060 |
Why?
| | Pregnancy | 2 | 2014 | 5690 | 0.060 |
Why?
| | Neutrophils | 1 | 2009 | 1233 | 0.060 |
Why?
| | Eosinophilia | 1 | 2005 | 184 | 0.060 |
Why?
| | Social Support | 1 | 2007 | 542 | 0.060 |
Why?
| | Betula | 1 | 2023 | 3 | 0.060 |
Why?
| | Family | 1 | 2007 | 585 | 0.060 |
Why?
| | Catastrophization | 1 | 2022 | 10 | 0.060 |
Why?
| | Antibodies | 1 | 2005 | 392 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 827 | 0.060 |
Why?
| | Histamine H1 Antagonists | 1 | 2002 | 33 | 0.060 |
Why?
| | Algorithms | 2 | 2007 | 1541 | 0.060 |
Why?
| | Communicable Disease Control | 1 | 2023 | 72 | 0.060 |
Why?
| | Mucous Membrane | 2 | 2014 | 113 | 0.050 |
Why?
| | Autoantigens | 1 | 2005 | 397 | 0.050 |
Why?
| | Prevalence | 2 | 2022 | 2326 | 0.050 |
Why?
| | Atrophy | 2 | 2013 | 164 | 0.050 |
Why?
| | Chile | 1 | 2021 | 16 | 0.050 |
Why?
| | Germ Cells | 1 | 2022 | 64 | 0.050 |
Why?
| | Colombia | 1 | 2021 | 43 | 0.050 |
Why?
| | Photography | 1 | 2022 | 93 | 0.050 |
Why?
| | Social Class | 1 | 2023 | 218 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2022 | 119 | 0.050 |
Why?
| | Blood Protein Electrophoresis | 1 | 1981 | 7 | 0.050 |
Why?
| | Nephelometry and Turbidimetry | 1 | 1981 | 16 | 0.050 |
Why?
| | Parents | 2 | 2022 | 1212 | 0.050 |
Why?
| | Mexico | 1 | 2021 | 165 | 0.050 |
Why?
| | Mupirocin | 1 | 2020 | 7 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 437 | 0.050 |
Why?
| | Information Dissemination | 1 | 2023 | 210 | 0.050 |
Why?
| | Retinoids | 1 | 2020 | 32 | 0.050 |
Why?
| | Language | 1 | 2023 | 271 | 0.050 |
Why?
| | Immunoglobulins | 1 | 1981 | 154 | 0.050 |
Why?
| | Inflammation | 1 | 2011 | 2566 | 0.050 |
Why?
| | Minority Groups | 1 | 2022 | 237 | 0.050 |
Why?
| | Cosmetics | 1 | 2020 | 7 | 0.050 |
Why?
| | Desmocollins | 1 | 2018 | 2 | 0.040 |
Why?
| | Desmogleins | 1 | 2018 | 5 | 0.040 |
Why?
| | Mutation Rate | 1 | 2018 | 25 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3174 | 0.040 |
Why?
| | Age of Onset | 1 | 2000 | 467 | 0.040 |
Why?
| | Mutagenesis | 1 | 2018 | 176 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 167 | 0.040 |
Why?
| | Health Personnel | 1 | 2023 | 588 | 0.040 |
Why?
| | Self Care | 1 | 2020 | 357 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2020 | 394 | 0.040 |
Why?
| | DNA Repair | 1 | 2018 | 198 | 0.040 |
Why?
| | Keratinocytes | 1 | 2018 | 227 | 0.040 |
Why?
| | Esophagus | 1 | 2018 | 237 | 0.040 |
Why?
| | Age Factors | 2 | 2014 | 2995 | 0.030 |
Why?
| | Melanocytes | 1 | 2016 | 66 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2016 | 95 | 0.030 |
Why?
| | Alemtuzumab | 1 | 2015 | 12 | 0.030 |
Why?
| | Myeloablative Agonists | 1 | 2015 | 22 | 0.030 |
Why?
| | Pain | 2 | 2015 | 735 | 0.030 |
Why?
| | Busulfan | 1 | 2015 | 14 | 0.030 |
Why?
| | Vidarabine | 1 | 2015 | 27 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 867 | 0.030 |
Why?
| | Keratin-16 | 1 | 2015 | 2 | 0.030 |
Why?
| | Keratin-6 | 1 | 2015 | 6 | 0.030 |
Why?
| | Skin Cream | 1 | 2014 | 7 | 0.030 |
Why?
| | Keratin-17 | 1 | 2015 | 4 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2022 | 829 | 0.030 |
Why?
| | Oils | 1 | 2014 | 19 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 61 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2016 | 369 | 0.030 |
Why?
| | Enzymes | 1 | 2015 | 66 | 0.030 |
Why?
| | HIV Infections | 1 | 2009 | 2459 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2016 | 828 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 420 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2015 | 415 | 0.030 |
Why?
| | Oral Medicine | 1 | 2013 | 1 | 0.030 |
Why?
| | Lip Diseases | 1 | 2013 | 6 | 0.030 |
Why?
| | Tongue Diseases | 1 | 2013 | 8 | 0.030 |
Why?
| | Palate | 1 | 2013 | 30 | 0.030 |
Why?
| | Risk Factors | 1 | 2006 | 9000 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1167 | 0.030 |
Why?
| | Ankyloglossia | 1 | 2012 | 1 | 0.030 |
Why?
| | Microstomia | 1 | 2012 | 1 | 0.030 |
Why?
| | Mouth Abnormalities | 1 | 2012 | 2 | 0.030 |
Why?
| | Dental Enamel Hypoplasia | 1 | 2012 | 6 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 770 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1440 | 0.030 |
Why?
| | Ulcer | 1 | 2012 | 28 | 0.030 |
Why?
| | Down-Regulation | 1 | 2015 | 627 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2014 | 408 | 0.030 |
Why?
| | Cicatrix | 1 | 2012 | 53 | 0.030 |
Why?
| | Back | 1 | 2011 | 10 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1166 | 0.030 |
Why?
| | Up-Regulation | 1 | 2015 | 872 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2012 | 324 | 0.030 |
Why?
| | Therapeutics | 1 | 2011 | 12 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 403 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2015 | 667 | 0.020 |
Why?
| | Necrosis | 1 | 2011 | 230 | 0.020 |
Why?
| | Fibroblasts | 1 | 2015 | 842 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2014 | 523 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2014 | 648 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2011 | 180 | 0.020 |
Why?
| | Elastic Tissue | 1 | 2009 | 8 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2015 | 963 | 0.020 |
Why?
| | Exons | 1 | 2010 | 307 | 0.020 |
Why?
| | Hair Follicle | 1 | 2009 | 52 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 4552 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 381 | 0.020 |
Why?
| | Neck | 1 | 2009 | 89 | 0.020 |
Why?
| | Vasodilator Agents | 1 | 2011 | 328 | 0.020 |
Why?
| | Resuscitation | 1 | 2011 | 252 | 0.020 |
Why?
| | Arm | 1 | 2009 | 106 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2016 | 4077 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1597 | 0.020 |
Why?
| | Preimplantation Diagnosis | 1 | 2007 | 4 | 0.020 |
Why?
| | Skin Diseases, Genetic | 1 | 2007 | 10 | 0.020 |
Why?
| | Heart Arrest | 1 | 2011 | 291 | 0.020 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2007 | 39 | 0.020 |
Why?
| | Wound Infection | 1 | 2007 | 31 | 0.020 |
Why?
| | Darbepoetin alfa | 1 | 2006 | 2 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6561 | 0.020 |
Why?
| | Malnutrition | 1 | 2007 | 66 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 3443 | 0.020 |
Why?
| | Fetal Diseases | 1 | 2007 | 148 | 0.020 |
Why?
| | Syndrome | 1 | 2005 | 344 | 0.020 |
Why?
| | Primary Health Care | 1 | 2014 | 1560 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2013 | 1864 | 0.010 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 304 | 0.010 |
Why?
| | Animals | 1 | 2002 | 33381 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 1981 | 253 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1636 | 0.010 |
Why?
|
|
Bruckner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|